J&J submit an application seeking an emergency use listing for its single-dose COVID-19 vaccine

An application seeking an emergency use listing for its single-dose COVID-19 vaccine has been submitted to the World Health Organisation by Johnson and Johnson (J&J). The submission follows J&J’s recently published safety and efficiency data from a Phase III trial evaluating the vaccine.

Twenty-eight days after the vaccination, J&J’s vaccine was sixty-six per cent effective overall in preventing moderate-to-severe COVID-19, shown in the ENSEMBLE trial – which was conducted in eight countries, with 44% of participants enrolled in the US, 15% in South Africa and 41% in Central and South America.

The efficacy rate was 57% and 66% effective in South Africa and Latin America, while 72% effective in the US.

J&J highlighted that the jab was 85% effective in preventing severe disease across all regions studied.